Law, LLP announces that it is investigating AMAG Pharmaceuticals (NASDAQ:
AMAG) and certain of its officers and directors for potential
breaches of fiduciary duties in connection with AMAG’s apparent failure
to disclose that users of the Company’s primary drug, Feraheme had
suffered adverse reactions, including hospitalizations and one possible
Investors who purchased AMAG stock before January 1, 2010 and have held
AMAG stock since, or anyone with information about this investigation
should contact Branham Law, LLP at email@example.com
or call (855) 722-5910.
On February 4, 2013, the United States First Circuit Court of Appeals
reversed the district court’s dismissal of these claims and reinstated
the action. After these failures to disclose were revealed, AMAG’s stock
fell over $7.00 per share. Subsequent disclosures regarding the
company’s rebate program resulted in a further drop of $4.02 per share.
Branham, Branham Law, LLP, 1-855-722-5910, 3900 Elm Street, Dallas,
Texas 75226 for additional information.